Who is sponsoring NCT05251974?

NCT05251974 is sponsored by Summa Health System.

What drugs are being tested in NCT05251974?

Interventions in NCT05251974: Quest beta blocker assay.

What condition does NCT05251974 study?

NCT05251974 studies Congestive Heart Failure, Medication Adherence.

Is NCT05251974 still recruiting?

NCT05251974 is currently terminated. Last updated 22 November 2023.

Last reviewed 2023-11-22 · How we verify

NCT05251974

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assay to Measure Beta Blocker Adherence

Terminated Last updated 22 November 2023

What this trial tests

trial testing Quest beta blocker assay in Congestive Heart Failure in 27 participants. Terminated before completion.

Timeline

2 March 2022

Primary endpoint
15 November 2023

15 November 2023

Quick facts

Lead sponsor	Summa Health System
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	27
Start date	2 March 2022
Primary completion	15 November 2023
Estimated completion	15 November 2023
Sites	1 location across United States

Drugs / interventions tested

Quest beta blocker assay

Conditions studied

Congestive Heart Failure — all drugs for Congestive Heart Failure →
Medication Adherence — all drugs for Medication Adherence →

Sponsor

Summa Health System

Who can join

Adults 18 to 89, any sex, with Congestive Heart Failure or Medication Adherence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Congestive Heart Failure

Currently open trials in the same condition.

NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
NCT06526884 — Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC) · NA · active not recruiting
NCT06495892 — PVP-Guided Decongestive Therapy in HF 2 · Phase 4 · recruiting
NCT06374277 — Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence · NA · recruiting
NCT05971225 — Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe) · NA · recruiting

Other Summa Health System trials

Trials by the same sponsor.

NCT05518877 — Low Dose Ketamine Infusion for Analgesia in the Emergency Department to Reduce Side Effects · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05251974 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Summa Health System
Last refreshed: 22 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05251974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing